11 okt: Mermaid Technology - Positiv ordreindgang, opjustering og organis..
14 okt: 7 Cool Fund
13-10-2010 10:20:05

Ad hoc reports in accordance with section 15 of the German Securities Trading Act (WpHG) - Dräger raises 2010 guidance

Drägerwerk AG & Co. KGaA /

Ad hoc reports in accordance with section 15 of the German Securities Trading

Act (WpHG) - Dräger raises 2010 guidance

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

For fiscal year 2010, Dräger is expecting an increase in net sales in the range of 10 percent (net sales 2009: EUR 1,911 billion). Net of currency effects, growth would then be in the mid single-digit range. After the company increased the forecast for the EBIT margin in June 2010 from originally 5 to 6 percent up to 7 to 8 percent, Dräger is now expecting an EBIT margin of 8 to 9 percent. As the cash settled option was replaced by an equity settled option on August 30, 2010, the impact from the Siemens cash option component has now been determined at EUR 11.8 million and is now included in this new guidance. The option component will not impact earnings in the future.

 

Now increased expectations for net sales and earnings are attributable to unexpectedly strong order intake, the unchanged positive development in the Americas and Asia-Pacific as well as favorable currency effects. The continuingly large share of high-margin equipment business in the medical division is a main contributor to higher profitability. The turnaround program is also having a highly positive effect and according to current estimates will contribute at least EUR 100 million to net earnings in 2010 against 2008. Originally the plan was to achieve a positive earnings effect of around EUR 70 million net in the current fiscal year and about EUR 100 million from 2011 on.

 

For 2011, Dräger intends to invest more into R&D, to implement projects more quickly and in particular to improve the marketing and sales organization. The company also assumes that one-time effects from the fiscal year 2010 will not recur. These include high levels of orders on hand from the previous year, strong order intake from large-scale projects, the sale of a deep-sea diving system for which an impairment charge was recorded for the full amount in 2009, the sale of software rights as well as the exceptionally advantageous product mix. External factors such as exchange rates are probably not going to benefit business in 2011 to the same degree. For 2011, Dräger is therefore not expecting to exceed the EBIT margin of the fiscal year 2010 amid slightly higher net sales. In the medium-term, the company is planning to grow stronger than the market and to achieve a sustained EBIT margin of at least 10 percent.

 

 

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55

23558 Lübeck, Deutschland

www.draeger.com

 

Investor Relations:

Vanina Herbst

Tel. +49 451 882-2685

vanina.herbst@draeger.com

 

Corporate Communications:

Burkard Dillig

Tel. +49 451 882-2185

burkard.dillig@draeger.com

 

 

Disclaimer

This ad-hoc release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

HUG#1451547

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 aug
OMXC20
  Dette indlæg er ikke langt, men det er vigtigt, så læs det grundigt.   Da jeg ved, der er en del, ..
79
22 aug
 
Siden finanskrisen har vi haft 8 korrektioner. Hvad kan vi se, læse og lære ud af tallene historisk?..
63
25 aug
OMXC20CAP
Alt godt; igen! Tag det helt roligt! Settle down people!    Den store reformator i verdensøkonomien:..
62
26 aug
RTX
Investor 1989, - nej tak, - jeg er ikke interesseret i at give 15 dollars for en analyse fra dig omk..
23
20:46
I:SP500
Indlægget her er kraftigt inspireret af overlaar@ (filter) og alpe med flere, kort og godt alle dem ..
21
24 aug
OMXC20CAP
Helt ærligt ... hvad piver I for?   Det er jo bare en boble der springer!   Husk nu, at siden 1986 h..
21
14:17
 
2.000.000 til 5.000.000 kr.
20
26 aug
VWS
Det er dog noget af det skægeste jeg længe har læst. Vindmøllegiganten Vestas er et af en stribe dan..
20
22 aug
 
@Dolly,   Jeg synes ikke jeg vil give råd om hvad man skal gøre lige nu, for det afhænger af hvilken..
20
14:15
 
fra 1.000.000 til 2.000.000 kr.
17

Novo indleder kæmpe fase 3-studie med GLP-1 tablet

26-08-2015 15:53:40
Novo Nordisk indleder et stort fase 3-program med sin langtidsvirkende GLP-1-analog Semaglutid i tabletform. Samtidig annonceres planer om en investering på 2 m..

Maersk Oil overvejer at lukke britisk olie-installation - NY3

26-08-2015 12:31:10
De lave oliepriser får A.P. Møller-Mærsks oliedivision, Maersk Oil, til at søge tilladelse om at lukke produktionen i Janice-installationen i den britiske del a..

Analytikerkorpset skruer på kursmål for FLSmidth efter regnskab

26-08-2015 09:31:11
Analytikerne hos HSBC, JPMorgan, Jyske Bank, Kepler Chevreux, Nordea, DNB og Handelsbanken har alle skruet på kursmålet for FLSmidth-aktien efter tirsdagens reg..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo Nordisk køber to amerikanske virksomheder - NY
2
Danmark/Danske: Renten kan stige allerede i dag
3
Aktier/tendens: Tegn på en grøn åbning
4
Kinesisk regering rygtes at holde hånden under aktierne
5
Danmark/Nordea: Venter dansk renteforhøjelse mod enden af året

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. august 2015 23:26:41
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150824.1 - EUROWEB5 - 2015-08-27 23:26:41 - 2015-08-27 23:26:41 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x